<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625415</url>
  </required_header>
  <id_info>
    <org_study_id>AC-PPEHP-89</org_study_id>
    <nct_id>NCT02625415</nct_id>
  </id_info>
  <brief_title>The Topical Application of Vitamin B6 in Palmar-Plantar Erythrodysesthesia</brief_title>
  <acronym>HFSB6</acronym>
  <official_title>A Double Blind Placebo Control Randomised Trial to Test the Effectiveness of Vitamin B6 in Hand Foot Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyprus University of Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cyprus University of Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to test the effectiveness of topical B6 cream in patients that
      developed Palmar-Plantar Erythrodysesthesia (Hand foot syndrome).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized double-blind, placebo-controlled study with 100 cancer patients
      that will receive chemotherapy treatment with capecitabine and/or pegylated liposomal
      doxorubicin. The selection of potential participants will be based on inclusion and exclusion
      criteria. Patients will be randomly allocated either to the treatment group or the placebo
      group. Treatment will be delivered daily (t.d.s) and assessments will take place at 0, 1, 2,
      3 and 4 weeks.

      The intervention group will receive the application of topical vitamin B6 cream to the hands
      and/or feet of the patients and the control group will receive the placebo.

      At both baseline and follow-up, patients in both groups will be assessed for their degree of
      palmar-plantar erythrodysesthesia, the Quality of Life, the need for dose-limiting due to PPE
      and Pain intensity using standardized rating scales. Data will be analysed with inferential
      and descriptive statistics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PPE grade</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>The grade of PPE will be assessed with a standardised three-grade system previously used in capecitabine clinical trials (Scheithauer et al 2003)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>The HRQoL of the patients will be assessed with the EORTC QLQ -C30 module which has been developed and validated explicitly for patients suffering from cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in relation to PPE</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>This is a quality of life scale specifically for patients experiencing radiation-induced PPE</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Activities of daily living</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Activities of daily living will be assessed with the Eastern Co-operative Oncology Group (ECOG)/WHO system</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment side-effects</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Any possible side-effect due to the treatment will be recorded</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Palmar-Plantar Erythrodysesthesia</condition>
  <arm_group>
    <arm_group_label>Vitamin B6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of B6 cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical application of B6 Placebo cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vitamin B6 cream</intervention_name>
    <description>Topical Vitamin B6 cream</description>
    <arm_group_label>Vitamin B6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Vitamin B6 cream</intervention_name>
    <description>Placebo Vitamin B6 cream</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult cancer patients (&gt;18)

          -  Patients receiving capecitabine and/or PLD as monotherapy or in combination with other
             agents

          -  Patients that will experience PPE grade 1 or above

          -  Willing to participate

          -  Ability to complete the psychometric assessments.

          -  A performance status of two or less on the Eastern Cooperative Oncology Group (ECOG

        Exclusion Criteria:

          -  Patients with hypersensitivity to Vitamin B.

          -  Patients with pre-existing dermatological condition affecting the hands or/and feet
             that may limit the interpretation of results

          -  Patients on oral Pyridoxine or nicotine patches

          -  Patients with a previous history of PPE

          -  Patients whose chemotherapy was discontinued for more than a week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreas Charalambous, PhD</last_name>
    <phone>+35725002011</phone>
    <email>andreas.charalambous@cut.ac.cy</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena Filippou, BSc, MSc (C)</last_name>
    <phone>97725755</phone>
    <email>e.filippou@nup.ac.cy</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Limassol General Hospital</name>
      <address>
        <city>Limassol</city>
        <country>Cyprus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simos Malas, MD</last_name>
      <phone>25 801100</phone>
      <email>Drmalas@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Despo Achilleos, RN</last_name>
      <phone>25 801100</phone>
      <email>despinaachilleos@cytanet.com.cy</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>American Medical Center</name>
      <address>
        <city>Nicosia</city>
        <zip>1311</zip>
        <country>Cyprus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Astras, MD, MRCP, MSc(UK)</last_name>
      <phone>+357 22 476 636</phone>
      <email>astras@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Cyprus</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cyprus University of Technology</investigator_affiliation>
    <investigator_full_name>Dr. Andreas Charalambous</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hand-Foot Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

